Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Exp Neurol. 2010 Apr 24;224(2):369–388. doi: 10.1016/j.expneurol.2010.04.013

Figure 8. Effect of valproate on rpFPI-induced PTE 5 weeks after injury.

Figure 8

A) Plots of mean seizure frequency (G1+G2+G3) in 8 individual rats before (week 4), during (week 5) and after (week 6) continuous subcutaneous infusion of VPA via osmotic minipump. Three animals became seizure free within 6 days of treatment at week 5, and were seizure free on post-injury week 6. B) Plots of mean duration of all seizures in the same rats before, during and after administration of VPA. Lines are truncated in those animals that did not seize during week 6 observation. Data in A–B are on a logarithmic scale. C) Mean logarithms of the frequencies of G1, G2 and G3 seizures before, during and after VPA administration (*p<0.05 versus week 4, paired t-test). D) Mean logarithms of time spent in G1, G2 and G3 seizures before, during and after VPA administration (*p<0.05 versus week 4, paired t-test). E) Mean logarithms of frequencies (Freq) and times spent in neocortical (G1+G2) seizure (TSS) before, during and after administration of VPA (*p<0.05 versus week 4, paired t-test). Displayed data include all detectable (longer than 0.8s) neocortical seizures. F) Effect of VPA on the activity of the neocortical focus demonstrated as in (E), but including only seizures longer than 5s. Note that the analyses displayed in (E) and (F) are similar but that the greater number of events included in (E) may result in enhanced sensitivity. G) Seizure frequency and [VPA]plasma in responders (filled squares) and non-responders (hollow circles) administered 480 mg*kg−1*day−1 VPA for 7 days. Mean frequencies are displayed for each 24h observation period (3 recordings per week) and refer to the scale to the left. Plasma levels refer to the scale to the right. The time scale is shared for both frequency and [VPA] data. Note that the responders exhibit a slow, steady decline in seizure frequency during VPA administration, and no seizures in the last recording during treatment and in the week after treatment. The value −1.45 represents the logarithm of the floor seizure-frequency value assigned to observations of no seizures in each 24h recordings.